Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPANOVA: TTFields + Sorafenib in Advanced HCC
NCT03606590Phase 2Completed
- Sponsor
- NovoCure
- Start
- Feb 2019
- Primary completion
- Jan 2021
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial, sponsored by NovoCure. Primary endpoint: Overall response rate at 30 months. Started Feb 2019; status: completed.
Beyond the preview
Go deeper on NCT03606590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606590.